ARTICLE | Clinical News
Empliciti elotuzumab regulatory update
February 8, 2016 8:00 AM UTC
EMA’s CHMP recommended Empliciti elotuzumab from Bristol-Myers Squibb and AbbVie to treat multiple myeloma (MM) in combination with Revlimid lenalidomide and dexamethasone in patients who have receiv...